Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 20
Filtrar
1.
Osteoporos Int ; 28(2): 577-584, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27682249

RESUMO

In hemodialysis patients, vertebral fractures were associated with elevated sclerostin levels, suggesting that sclerostin could reflect bone fragility in these patients. INTRODUCTION: Fragility fractures are common in hemodialysis patients. The aims of our study were to determine the prevalence of vertebral fracture and analyze associations between sclerostin serum levels and vertebral fractures in hemodialysis patients. METHODS: Ninety-two hemodialysis patients and 100 controls matched for age and sex were studied. Bone mineral density was measured by ultrasonography at non-dominant heel. The markers of bone turnover included serum osteocalcin, C-terminal telopeptide, and sclerostin. All participants underwent radiography of the thoracic and lumbar spine to ascertain the presence of vertebral fractures. RESULTS: Bone ultrasound parameters at calcaneus were significantly lower in hemodialysis patients compared with controls; bone turnover markers and parathyroid hormone level were significantly higher, while serum of 25-OH-D3 was significantly lower in hemodialysis group. One or more moderate or severe vertebral fractures were found in 38 hemodialysis patients, whereas in control group, 10 patients had a vertebral fracture. In hemodialysis group, the comparison between patients with and without vertebral fractures showed that the patients with vertebral fractures had the serum sclerostin levels statistically higher than patients without vertebral, while serum levels of 25-OH-D3 was significantly lower in patients with vertebral fractures compared to the patients without vertebral fractures. Multivariate analysis disclosed that sclerostin levels were associated with an increased risk of vertebral fractures in hemodialysis patients after adjusting for multiple variables. CONCLUSIONS: Our data shows high prevalence of vertebral fractures in hemodialysis patients and that it is associated with elevated sclerostin levels, reflecting bone fragility in these patients.


Assuntos
Proteínas Morfogenéticas Ósseas/sangue , Fraturas por Osteoporose/etiologia , Diálise Renal/efeitos adversos , Fraturas da Coluna Vertebral/etiologia , Deficiência de Vitamina D/complicações , Proteínas Adaptadoras de Transdução de Sinal , Idoso , Idoso de 80 Anos ou mais , Densidade Óssea/fisiologia , Estudos de Casos e Controles , Feminino , Marcadores Genéticos , Calcanhar/diagnóstico por imagem , Humanos , Masculino , Pessoa de Meia-Idade , Osteoporose/complicações , Osteoporose/diagnóstico por imagem , Osteoporose/fisiopatologia , Fraturas por Osteoporose/sangue , Fraturas por Osteoporose/diagnóstico por imagem , Fraturas por Osteoporose/fisiopatologia , Radiografia , Medição de Risco/métodos , Fraturas da Coluna Vertebral/sangue , Fraturas da Coluna Vertebral/diagnóstico por imagem , Fraturas da Coluna Vertebral/fisiopatologia , Ultrassonografia , Calcificação Vascular/sangue , Calcificação Vascular/etiologia , Deficiência de Vitamina D/fisiopatologia
2.
J Biol Regul Homeost Agents ; 29(2 Suppl 1): 55-7, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26634588

RESUMO

High mobility group box 1, an evolutionary ancient protein conserved in the eukaryotic kingdom, exerts intra- and extra- cellular functions, orchestrating a homeostatic defensive response in challenged tissues. Its action associated with various inflammatory cells is essential for the occurrence, progression, and persistence of asthma, rhinitis, and nasal polyposis. The recent discovery of High mobility group box 1, as a critical mediator of inflammation, stimulated an increasing interest in the field of inflammation research, suggesting new therapies for atopic and non-atopic inflammatory processes.

3.
J Biol Regul Homeost Agents ; 28(3): 367-75, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25316125

RESUMO

Puberty is a complex, coordinated biological process with multiple levels of regulations. The timing of puberty varies greatly in children and it is influenced by environmental, endocrine and genetic factors. Precocious puberty (PP) is an important issue, affecting between 1 in 5.000-10.000 children. The physiopathological mechanism is still unknown. From an etiological point of view, PP may be subdivided into gonadotropin-releasing hormone (GnRH) -dependent and independent causes. GnRH-dependent PP, often called central precocious puberty (CPP), is based on hypothalamic-pituitary-gonadal axis activation associated with progressive pubertal development, accelerated growth rate and advancement of skeletal age. Conversely, peripheral precocious puberty (PPP) is related to sex steroid exposure, independently of hypothalamic-–pituitary-–gonadal (HPG) axis activation. Kisspeptins play a central role in the modulation of GnRH secretion with peripheral factors that influence the timing of puberty, such as adipokines and endocrine disrupting chemicals. Moreover, PP could be related to genetic disorders, involving pivotal genes of the HPG axis. The standard test used to verify HPG activity is the gonadotropin response to administered GnRH analogs. We describe the physiopathological mechanisms of PP and its clinical implications, analysing diagnostic flow-chart and new potential biomarkers that could reveal PP. An update of the current literature was also carried out regarding the recent novelty for treatment.


Assuntos
Hormônio Liberador de Gonadotropina/metabolismo , Gonadotropinas/metabolismo , Gônadas , Sistema Hipotálamo-Hipofisário , Puberdade Precoce , Puberdade , Biomarcadores/metabolismo , Feminino , Gônadas/metabolismo , Gônadas/patologia , Humanos , Sistema Hipotálamo-Hipofisário/metabolismo , Sistema Hipotálamo-Hipofisário/patologia , Masculino , Puberdade Precoce/metabolismo , Puberdade Precoce/patologia , Puberdade Precoce/terapia
4.
Eur Rev Med Pharmacol Sci ; 15(2): 111-21, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21434477

RESUMO

Because of progressive population ageing and epidemic diffusion of type 2 diabetes mellitus in industrialized Countries, we are attending a growing incidence of end stage renal disease. This phenomenon has induced researchers to study potential alternative methods of renal function replacement. Actually, only dialytic methodics and renal transplant make possible survival of patients with terminal uremia, but both these therapeutic approaches show important limitations. The ideal solution would be represented by the possibility to "regenerate" the injured organ. This is the purpose of Regenerative Nephrology, a new medical domain which tries to develop new therapies through stimulation and induction in humans of regenerative processes already observed in other species, like reptiles and fishes. Such an ambitious and fascinating purpose requires a deep knowledge of the intricate networks which regulate the production of the hormones and mediators involved in the tissue regenerative processes. In this field the kidney embryonic development phases can represent a fundamental study model to acquire information about the reparative mechanisms of the structure and function of this excretory organ.


Assuntos
Nefropatias/terapia , Rim/fisiologia , Regeneração , Animais , Humanos , Rim/embriologia , Glomérulos Renais/embriologia , Túbulos Renais/embriologia , Células-Tronco/fisiologia
5.
J Nephrol ; 34(6): 1915-1924, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33761123

RESUMO

INTRODUCTION: Alport syndrome (ALP) is a rare genetic condition characterized by progressive involvement of the basal membranes and renal dysfunction. The purpose of the study was to evaluate urinary (u) and serum (s) levels of tumor growth factor (TGF)-beta(ß) and high mobility group box (HMGB)-1 in ALP patients with normal renal function, albuminuria and proteinuria. METHODS: A prospective, single-center study was performed with a follow-up period of 12 months, enrolling 11 pediatric ALP patients and 10 healthy subjects (HS). Normal values of serum creatinine, albuminuria and proteinuria, as well as unaltered estimated glomerular filtration rate (eGFR) were required at enrollment. RESULTS: ALP patients had significantly higher levels of serum and urinary HMGB1 compared to HS. The same trend was observed for TGF-ß1, with higher values in ALP patients than in HS. HMGB1 and TGF-ß1 correlated with each other and with markers of renal function and damage. Urinary biomarkers did not correlate with eGFR, whereas sHMGB1 and sTGF-ß1 were negatively related to filtration rate (r: - 0.66; p = 0.02, r: - 0.96; p < 0.0001, respectively). Using proteinuria as a dependent variable in a multiple regression model, only the association with sTGF-ß1 (ß = 0.91, p < 0.0001) remained significant. CONCLUSIONS: High levels of HMGB1 and TGF-ß1 characterized ALP patients with normal renal function, highlighting the subclinical pro-fibrotic and inflammatory mechanisms triggered before the onset of proteinuria. Further studies are needed to evaluate the role of HMGB1 and TGFß-1 in ALP patients.


Assuntos
Proteína HMGB1 , Nefrite Hereditária , Criança , Humanos , Estudos Prospectivos , Proteinúria , Fator de Crescimento Transformador beta , Fator de Crescimento Transformador beta1
6.
Eur J Clin Invest ; 40(3): 273-6, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20415702

RESUMO

Neutrophil gelatinase-associated lipocalin (NGAL), a small 25 kDa stress-protein released from injured tubular cells after various damaging stimuli, is already known by nephrologists as one of the most promising biomarkers of incoming Acute Kidney Injury. Moreover, recent studies seem to suggest a potential involvement of this factor also in the genesis and progression of chronic kidney diseases. This brief review explores the new interesting involvement of NGAL in the experimental and clinical field of cardiovascular diseases, such as the pathogenesis and clinical manifestations of atherosclerosis, acute myocardial infarction and heart failure. It does not seem difficult that, in the next future, NGAL may become a new missing link between the kidney and the cardiovascular system.


Assuntos
Doenças Cardiovasculares/sangue , Lipocalinas/sangue , Proteínas Proto-Oncogênicas/sangue , Doença Aguda , Proteínas de Fase Aguda , Aterosclerose/sangue , Biomarcadores/sangue , Doenças Cardiovasculares/diagnóstico , Feminino , Insuficiência Cardíaca/sangue , Humanos , Lipocalina-2 , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/sangue , Valor Preditivo dos Testes , Risco
8.
Eur J Clin Invest ; 39(11): 993-9, 2009 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-19614951

RESUMO

BACKGROUND: Erythropoietin (EPO), the main haematopoietic growth factor for the proliferation and differentiation of erythroid progenitor cells, is also known for its angiogenic and regenerative properties. MATERIALS AND METHODS: In this study, we aimed to test the regenerative effects of EPO administration in an experimental model of Sea bass (Dicentrarchus labrax) subjected to amputation of the caudal fin. RESULTS: Erythropoietin-treated fishes (3000 UI of human recombinant EPO-alpha immediately after cutting and after 15 days) showed an increased growth rate of their fins compared with those untreated (anova variance: P: 0.01 vs. P: 0.04). By analysing fin length at established times (15 and 30 days after cut), EPO-treated fishes always showed an increased length compared with untreated ones (T-15: 1.1 +/- 0.2 vs. 0.7 +/- 0.2 cm, P: 0.03; T-30: 1.9 +/- 0.3 vs. 1.2 +/- 0.2 cm, P: 0.01). Moreover, exogenous EPO administration induced an enormous increase in EPO-blood levels at each observation time (T-15: 2240 +/- 210 vs. 16.7 +/- 1.8 mU mL(-1), P < 0.001; T-30: 2340 +/- 190 vs. 17.1 +/- 1.9 mU mL(-1), P < 0.001), whereas these levels remained quite unmodified in untreated fishes. Immunochemical analyses performed by confocal laser scanning microscopic observations showed an increased expression of EPO-receptors and PECAM-1 (an endothelial surface marker of vessels sprout) in the regenerating tissue, whereas no signs of inflammation or fibrosis were recognisable. CONCLUSIONS: All these findings confirm EPO as a new factor involved in regenerative processes, also suggesting a potential, future utility for new therapeutical applications in the field of human regenerative medicine.


Assuntos
Eritropoetina/metabolismo , Peixes , Neovascularização Fisiológica/fisiologia , Regeneração/fisiologia , Animais , Bass , Eritropoetina/genética , Imuno-Histoquímica , Modelos Biológicos , Neovascularização Fisiológica/genética , Regeneração/genética , Medicina Regenerativa
9.
Clin Microbiol Infect ; 21(4): 368.e1-9, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25658530

RESUMO

Airway inflammation plays a central role in cystic fibrosis (CF) lung disease, and biomarkers of inflammation, such as high-mobility group box 1 (HMGB1) could be used to monitor disease activity. The main aim of this study was to confirm the role of HMGB1 in CF patients, correlating its serum and sputum levels with pulmonary function and inflammation. Serum and sputum HMGB1 were evaluated in a cohort of 31 CF patients and 30 non-smoking healthy subjects (HS group). Acute pulmonary exacerbation events and lung function decline have been also evaluated during a 3-year follow-up period. Serum HMGB1 levels were significantly higher than those measured in HS, such as sputum HMGB1. Kaplan-Meier survival curves revealed that patients with high HMGB1 values experienced a significantly faster evolution to decline of lung function. A multiple Cox regression analysis assessed that an increase of serum HMGB1 was associated with 5% increased risk of pulmonary disease progression, whereas elevated sputum HMGB1 was related to a 10% increased risk of lung function decline. In CF patients, HMGB1 closely reflects the entity of pulmonary impairment and represents a strong and independent risk marker for progression of lung function decline.


Assuntos
Broncopneumonia/patologia , Fibrose Cística/complicações , Proteína HMGB1/análise , Proteína HMGB1/sangue , Inflamação/patologia , Adolescente , Adulto , Broncopneumonia/diagnóstico , Criança , Pré-Escolar , Feminino , Humanos , Inflamação/diagnóstico , Masculino , Estudos Prospectivos , Testes de Função Respiratória , Soro/química , Escarro/química , Adulto Jovem
10.
Curr Med Chem ; 21(7): 849-54, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24059228

RESUMO

The synthesis of recombinant human erythropoietin has marked a turning point in the treatment of anaemia secondary to chronic kidney disease. However, the potentially fatal cardio- and cerebrovascular complications of the intake of high-doses of ESAs (erythropoiesis-stimulating agents), such as those observed in athletes who resort to doping, reason out the ever-prevalent debate concerning the balance between the risks and benefits of ESA administration for therapeutic purposes. Hence, there is still a discussion as to what values haemoglobin should ideally be maintained at. Additional concerns arise in cancer patients due to the ability of erythropoietin to act as an angiogenic and, in general, as a cell growth factor, because this might favour the progression of neoplastic disease. We summarized the prominent points of the latest guidelines on the management of anaemia in nephropathic patients, also identifying the possible risks that may result from the tendency to aim at too low haemoglobin levels.


Assuntos
Anemia/tratamento farmacológico , Eritropoetina/uso terapêutico , Anemia/etiologia , Eritropoetina/genética , Eritropoetina/metabolismo , Guias como Assunto , Humanos , Falência Renal Crônica/complicações , Falência Renal Crônica/patologia , Neoplasias/complicações , Neoplasias/patologia , Proteínas Recombinantes/biossíntese , Proteínas Recombinantes/genética , Proteínas Recombinantes/uso terapêutico
11.
Diabetes Metab ; 40(3): 224-8, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24485160

RESUMO

AIM: This report highlights the metabolic, endocrine and cardiovascular comorbidities in a case of familial partial lipodystrophy (FPLD), and also evaluates the efficacy and safety of metformin therapy. METHODS: Mutational analysis was carried out of the LMNA gene in a teenage girl with an FPLD phenotype. Insulin resistance, sex hormones and metabolic parameters were also evaluated, and echocardiography, electrocardiography and 24-h blood pressure monitoring were also done. RESULTS: The patient showed atypical fat distribution, insulin resistance and hypertrophic cardiomyopathy. Physical examination revealed muscle hypertrophy with a paucity of fat in the extremities, trunk and gluteal regions, yet excess fat deposits in the face, neck and dorsal cervical region. LMNA sequencing revealed a heterozygous missense mutation (c.1543A>G) in exon 9, leading to substitution of lysine by glutamic acid at position 515 (K515E). Moderate hypertension and secondary polycystic ovary syndrome were also assessed. Treatment with metformin resulted in progressive improvement of metabolic status, while blood pressure values normalized with atenolol therapy. CONCLUSIONS: Very rapid and good results with no side-effects were achieved with metformin therapy for FPLD. The association of an unusual mutation in the LMNA gene was also described.


Assuntos
Amenorreia/genética , Doenças Cardiovasculares/genética , Lamina Tipo A/genética , Lipodistrofia Parcial Familiar/genética , Mutação de Sentido Incorreto , Síndrome do Ovário Policístico/genética , Adolescente , Amenorreia/tratamento farmacológico , Distribuição da Gordura Corporal , Doenças Cardiovasculares/tratamento farmacológico , Análise Mutacional de DNA , Feminino , Humanos , Hipoglicemiantes/uso terapêutico , Resistência à Insulina , Lamina Tipo A/metabolismo , Lipodistrofia Parcial Familiar/tratamento farmacológico , Lipodistrofia Parcial Familiar/metabolismo , Lipodistrofia Parcial Familiar/fisiopatologia , Metformina/uso terapêutico , Fenótipo , Síndrome do Ovário Policístico/tratamento farmacológico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA